Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age
Daniel González(University of North Carolina at Chapel Hill), Michael Cohen‐Wolkowiez(Duke University), Sailaja Puttagunta(3D Biomatrix (United States)), Xilla T. Ussery(University of North Carolina at Chapel Hill), John S. Bradley(Rady Children's Hospital-San Diego), Kevin Watt(University of Utah), Michael W. Dunne(University of North Carolina at Chapel Hill), Laura P. James(University of Arkansas for Medical Sciences), Li Zhang(China Tobacco), Jennifer Murphy(Clinical Research Institute), Jeffrey L. Blumer(University of Toledo), Ram Yogev(Northwestern University), Debra L. Palazzi(Baylor College of Medicine), Varsha Bhatt‐Mehta(University of Toledo Medical Center)
Cited by 44
Related Papers
Natural selection on <i>EPAS1</i> ( <i>HIF2α</i> ) associated with low hemoglobin concentration in Tibetan highlanders
|Proceedings of the National Academy of Sciences|2010|854
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
Camelid genomes reveal evolution and adaptation to desert environments
|Nature Communications|2014|317